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The eﬀects of bimatoprost on aqueous humor dynamics were quantiﬁed in monkey eyes. Uveoscleral outﬂow was measured by the
anterior chamber perfusion method, using FITC-dextran. Total outﬂow facility was determined by the two-level constant pressure
method. Aqueous ﬂow was measured with a scanning ocular ﬂuorophotometer. Uveoscleral outﬂow was 0.96 ± 0.19μLm i n
−1 in
vehicle-treated eyes and 1.37±0.27μLm i n
−1 (n = 6; P<. 05) in eyes that received bimatoprost 0.01% b.i.d. × 5d a y s .B i m a t o p r o s t
had no eﬀect on total outﬂow facility, which was 0.42 ± 0.05μLm i n
−1 at baseline and 0.42 ± 0.04μLm i n
−1 after bimatoprost
treatment. Bimatoprost had no signiﬁcant eﬀect on aqueous humor ﬂow. This study demonstrates that bimatoprost increases
uveoscleral outﬂow but not total outﬂow facility or aqueous humor ﬂow, indicating that it lowers intraocular pressure in ocular
normotensive monkeys by a mechanism that exclusively involves uveoscleral outﬂow.
1.Introduction
Bimatoprost (Lumigan) is a highly eﬃcacious ocular
hypotensive agent, [1–5] with a unique pharmacology [1].
It mimics the activity of the prostaglandin ethanolamides
(prostamides), which are formed from the endocannabinoid
anandamide by cyclo-oxygenase-2 (COX-2) [6–9]. Several
studies have demonstrated that the pharmacology of the
prostamides and bimatoprost is distinct from that of the
prostaglandins [1, 10–16] and the endocannabinoids [17].
The diﬀerentiated pharmacology of bimatoprost is also
manifest in the clinical setting where it lowers intraocular
pressure (IOP) in open-angle glaucoma and ocular hyper-
tensive patients who are nonresponders to the FP receptor
agonist prodrug latanoprost [18–20].
Measurement of uveoscleral outﬂow in patients, of
necessity, is derived indirectly. It is calculated from mea-
surements of aqueous humor ﬂow, outﬂow facility, and an
assumed typical value for episcleral venous pressure. Direct
measurement of uveoscleral outﬂow requires enucleation of
the eyes and measurement of a radiolabeled or ﬂuorescent
markerinanteriorsegmenttissues.Thepurposeofthisstudy
was to provide a direct measurement of uveoscleral outﬂow
in primates, of a nonhuman variety. Total outﬂow facility
wasalso measureddirectly by thetwo-levelconstantpressure
method.Forcompletion,aqueoushumorﬂowwasmeasured
ﬂuorphotometrically.
2.MaterialsandMethods
Ocular normotensive cynomolgus monkeys (Macaca fasci-
culate) of both sexes and weighing between 2.2 and 4.0kg
were used for these studies. All experiments were performed
according to the ARVO statement for the Use of Animals
in Ophthalmic and Vision Research. All animals were
determined as suitable for study according to prior slit-lamp
biomicroscopy. For measurement of total outﬂow facility
and uveoscleral outﬂow, one eye received 25μL of 0.01%
bimatoprost at ∼6 A.M. and again at ∼2P . M .t op r o v i d e
B.I.D. dosing. The contralateral eye received vehicle (5mM
TRIS-HCl/0.1% polysorbate 80) in an identical manner.
Each animal received a total of 9 doses in each eye over a four
and one-half day period. Between 5 and 7 hours after the2 Journal of Ophthalmology
ﬁnal dose, the animals were anesthetized by intramuscular
injection of 0.3mL/kg of a mixture of ketamine (25mg/mL)
and xylazine (10mg/mL) to provide deep anesthesia and an
absence of eye movements. Anesthetic was supplemented
during the course of the experiment at a dose of 0.1mL/kg of
the mixture when the level of anesthesia was reduced to the
point where ﬁrst signs of slow eye movements and blinking
became apparent. Supplemental doses of the anesthetic
mixture were typically given 45–60 minutes after the initial
dose or even earlier in some instances. Vital signs, heart rate
and body temperature, were continuously monitored.
Outﬂow facility studies were performed as follows. After
a stable and deep level of anesthesia had been achieved,
both eyes were cannulated through the cornea with one
25-gauge stainless steel needle by using a needle gun. The
IOP was determined with a calibrated pressure transducer
system. Outﬂow facility was then determined with a 2-
level constant pressure infusion method described by B´ ar´ any
[21]. In brief, the anterior chamber was connected in series
to a pressure transducer and a ﬂuid reservoir containing
a modiﬁed mock artiﬁcial aqueous humor solution [22].
The pressure in the eye was altered at 10-minute intervals
between two diﬀerent pressure levels approximately 2.5 (p1)
and 10mm Hg (p2) above the “real” IOP level. “Real” IOP in
this context describes the IOP that would be present in the
eye if the pressure was not artiﬁcially maintained with the
reservoir. For each 10-minute measurement period at p1 or
p2,theﬂowrateofﬂuidfromthereservoirwasdeterminedas
F1 or F2,r e s pe ct i v e l y .F l o wra t e sw e r ec a l c u l a t e da sF = ΔW/t
with ΔW representing the weight diﬀerence of the reservoir
between the beginning and end of the measurement period
and t representing the duration of the period. Total outﬂow
facility C could then be calculated with the equation
C =
F2 −F1 
p2 − p1
. (1)
Total outﬂow facility values in each eye were averaged
over 5 measurement periods. The outﬂow facility studies
weredonetwiceinthesameanimalsapproximately4months
apart. Total outﬂow facility was ﬁrst measured in na¨ ıve,
untreated animals (to obtain a “baseline”) and four months
later after 5 days of bimatoprost unilateral treatment (as
described above).
To determine the eﬀect of bimatoprost on uveoscleral
outﬂow, we used the anterior chamber perfusion method
originally developed by Bill [23] and then modiﬁed by
Toris et al. [24] using a ﬂuorescein-tagged tracer instead of
radiolabeled albumin. Each eye was cannulated with three
25-gauge needles, two of which were connected to 5mL
gastight syringes mounted in a Harvard reciprocal syringe
pump, the third was connected to an open ﬂuid reservoir
with an inline pressure transducer to record IOP. The Har-
vard reciprocal pump allowed the perfusion of the anterior
chamber at a predetermined ﬂow rate without aﬀecting IOP
by virtue of the perfusion process. Both eyes were perfused
for 30 minutes with a mock aqueous humor solution [22]
containing 0.7% (1 × 10
−4M) FITC-dextran 70,000 as a
tracer. To provide for a quick exchange of the anterior
chamber content with the tracer, the eyes were perfused for
the ﬁrst 5 minutes at a rate of 0.2mL/min and then during
the remaining 25 minutes at a rate of 0.05mL/min. The
perfusates from those two perfusion periods were collected
separately as primary and secondary perfusate, respectively.
The IOP in both eyes was set during the anterior chamber
perfusion at approximately 12mmHg via the open reservoir.
At the conclusion of the 30-minute perfusion period the
animal was euthanized with an overdose of Eutha-6 CII
(2mL). Both eyes were then perfused for approximately 10
minutes with mock aqueous humor solution, without tracer,
to wash the tracer out of the anterior chamber. The eyes
were then enucleated and immediately dissected into the
following tissues: anterior sclera, posterior sclera (posterior
to ora serrata), extraocular tissues, ciliary body, choroid,
retina,vitreoushumor,andotherﬂuidsincludingwashﬂuid.
Cornea, lens, and iris were excluded from the measurements
because these tissues are not thought to contribute to
uveoscleral outﬂow.
T h ea m o u n to ft r a c e rw a sd e t e r m i n e di ne a c ho c u l a r
tissue separately. For that purpose, each tissue was homog-
enized in Dulbecco’s phosphate-buﬀered saline (D-PBS).
The FITC-dextran concentration in tissue homogenates was
determined with a Perkin-Elmer LS-50B spectrometer using
excitation and emission wavelengths of 493 and 515nm,
respectively, and 5.0nm excitation and emission slits. Total
uveoscleral outﬂow (Fu) was calculated with equation
Fu = Σ(tissue-FITC) ×

perfusate-FITC
−1 ×time
−1,( 2 )
where Σ(tissue-FITC) represents the total amount of FITC-
dextran present in all ocular tissues, [perfusate-FITC] rep-
resents the actual FITC-dextran concentration in the ante-
rior chamber perfusate (which was collected as secondary
perfusate with the receiving syringe during the 25-minute
perfusion period), and time represents the duration of the
perfusion (i.e., 30 minutes).
Statistical analysis was performed with Students’s t-test
for paired observations using the software package StatView
Version 4.51 for Windows. Diﬀerences were assumed to be
statistically signiﬁcant for P<. 05.
Aqueous ﬂow was measured ﬂuorophotometrically with
a Fluorotron instrument (OcuMetrics, Mountain View, CA).
The animals were brieﬂy restrained during the procedure in
custom-designed chairs. Background autoﬂuorescence scans
were taken on the afternoon prior to the ﬂuorophotometry
experiment. The experiment was commenced by giving one
dropof0.5%proparacaine(Ophthetic,Allergan)toeacheye.
Fiveminuteslateradropofproparacainefollowedby2μLN a
ﬂuorescein (2%) was given. This proparacaine/ﬂuorescein
dosing procedure was repeated four times at ﬁve minutes
intervals. This procedure “loaded” the eye with ﬂuorescein
and provided steady-state conditions for the experiment
on the following day. Fluorphotometric measurements were
performed 7 times, one hour apart, on the following day.
Each eye was scanned at least twice per reading. Ketamine
(1.4mg/kg) was injected intramuscularly 5 minutes before
each scan.
In order to calculate aqueous humor ﬂow, values for
anterior chamber depth and corneal thickness and curva-
ture were obtained. Anterior chamber depth and cornealJournal of Ophthalmology 3
Table 1: Eﬀect of bimatoprost (0.01%) administered twice daily for
5 days on total outﬂow facility in (μLm i n −1 mmHg−1) cynomolgus
monkeys, n = 6 (Mean ± SEM).
Total outﬂow facility (μLm i n −1 mm Hg−1)
Vehicle (OS) Treated (OD)
Baseline 0.46 ±0.03 0.42 ±0.05
Treatment 0.37 ±0.02 0.42 ±0.04
Table 2: Eﬀect of bimatoprost (0.01%) administered twice daily for
5 days on uveoscleral outﬂow (μLm i n −1) in cynomolgus monkeys
∗P<. 05, n = 6 (Mean ± SEM).
Uveoscleral outﬂow (μLm i n −1)
Bimatoprost 1.37
∗ ±0.27
Vehicle 0.96 ±0.20
thickness were determined by pachymetry using a Haag-
Streit slit lamp. Corneal curvature was determined using a
keratometer. These values allowed anterior chamber volume
to be calculated. Aqueous humor ﬂow was obtained by
software written for the IBM or Macintosh by M.A. Croft
(University of Wisconsin) according to equations developed
by Yablonski [25].
For aqueous humor ﬂow studies with bimatoprost,
(0.1%) the drug was administered twice on the day before
the ﬂow experiment with a 6-hour interval between doses
and again on the morning of the day of the ﬂow experiment
in a diﬀerent series of experiments. Timolol, employed as a
reference drug, was administered once on the day of the ﬂow
experiment in a separate series of the experiments involving
unilateral administration of timolol, the contralateral eye
receiving the vehicle as a control.
3. Results andDiscussion
3.1. Aqueous Humor Dynamics. The eﬀects of bimatoprost
(0.01%) on total outﬂow facility and uveoscleral outﬂow
in monkeys were determined approximately 6 hours after
the 9th dose of treatment on day 5 of a 5-day BID dosing
regimen.
In the untreated, na¨ ıve study animals total outﬂow
facility was similar in the right and left eye and is shown
as “Baseline” values in Table 1. No signiﬁcant eﬀect on total
outﬂow facility was observed after unilateral treatment with
bimatoprost (0.01%) as shown in Table 1. The uveoscleral
outﬂow in the eyes treated with bimatoprost (0.01%) was
1.37 ± 0.27μL/min compared to 0.96 ± 0.20μL/min in
the contralateral control eyes as shown in Table 2. This
represents a 42% increase.
The aqueous humor ﬂow rates comparing the eﬀects
of 3 × 0.1% bimatoprost and a single dose of timolol are
providedinTable 3.Althoughtimolol,employedasapositive
control, eﬀectively suppressed aqueous humor inﬂow by
about 42%, bimatoprost exerted no meaningful eﬀect.
Table 3: Comparison of the eﬀect of timolol (0.5%) and bimato-
prost (0.1%) on aqueous humor ﬂow (μL/min−1) in cynomolgus
monkeys, ∗P<. 05, n = 6 (Mean ± SEM).
Aqueous humor ﬂow (μLm i n −1)
Timolol (0.5%) Bimatoprost (0.1%)
Vehicle 1.64 ±0.14 1.41 ±0.07
Drug 0.91 ±0.09 1.497 ±0.07
4. Discussion
Studies in normal human volunteers and in patients
with ocular hypertension or glaucoma have shown that
bimatoprost increases both pressure-sensitive and pressure-
insensitive aqueous humor outﬂow. The latter is presumed
to reﬂect uveoscleral outﬂow [26, 27]. These clinical deter-
minations of uveoscleral outﬂow were calculated from mea-
surements of aqueous humor ﬂow and trabecular outﬂow
using the Goldmann equation, since direct measurement
of uveoscleral outﬂow requires enucleation and dissection
of ocular tissues. Thus, one objective of proﬁling the
eﬀects of bimatoprost on monkey aqueous humor dynamics
was to provide direct assessment of uveoscleral outﬂow.
Bimatoprost, in a dosing regimen that produces profound
and long-lasting decreases in intraocular pressure in normal
monkeys [1], was found to produce a signiﬁcant increase in
uveoscleral outﬂow. This direct physiological measurement
of uveoscleral outﬂow, together with morphological studies
[28], is consistent with the notion that bimatoprost does
indeed increase uveoscleral outﬂow.
Bimatoprost exerted no meaningful eﬀect on total out-
ﬂow facility or aqueous humor ﬂow in cynomolgus monkeys
and it may be presumed that increased uveoscleral outﬂow
provides a singular explanation for its ocular hypotensive
eﬀects in this species. The dosing regimens used in this
study are experimental and diﬀer from that currently used
clinically, which is 0.03% once daily. It is diﬃcult to oﬀer a
straightforward explanation for the inability of total outﬂow
facility results obtained in cynomolgus monkeys to predict
marked increases in tonographic outﬂow in humans. They
do not necessarily equate. It is possible that the anesthesia,
which is obligatory for direct measurement of total outﬂow
facility in monkeys, may have blunted trabecular outﬂow
by aﬀecting the normal function of trabecular meshwork
cells and endothelial cells of Schlemm’s canal. This possible
explanation should, however, be viewed with some caution.
Sex and age do not provide an obvious explanation; the
ages of the normal volunteers [26] and the monkeys used in
these studies were comparable taking into account the life-
span of the two species. It is most unlikely that the dosing
regimen used in the monkey studies (0.01% bimatoprost,
twice daily for 5 days) fails to produce changes in outﬂow
facility that can be observed in the clinical setting with a
dosing regimen of 0.03% once daily. Bimatoprost (0.01%)
given twice daily produces profound eﬀects on monkey IOP
(1). Species diﬀerence [29] with respect to pharmacological
control of aqueous humor dynamics may provide a more4 Journal of Ophthalmology
plausibleexplanation,despitethefactthatmonkeysandman
are phylogenetically very close.
The monkey is preferred for ocular studies by virtue of
possessing an ocular anatomy and physiology that appears
very similar to that observed in humans, the only obvious
diﬀerence being the size of the globe. There is, however,
some evidence to suggest that the monkey does not nec-
essarily always mimic the human eye in all respects. The
α2 adrenoceptor agonist brimondine provides a further
example. In monkeys there is a centrally mediated bilateral
response to brimondine [29], that is not apparent in human
subjects [30]. The 11,15-dipivaloyl ester of PGF2α exhibited
acceptable eﬃcacy in monkeys [31]b u tw a sd e v o i do fa n y
ocular eﬀects in humans (unpublished data). Prostanoid
FP receptor agonists such as travoprost and latanoprost
have also been reported to exert no meaningful eﬀect
on trabecular outﬂow in monkeys [32, 33]. Eﬀects on
presumed trabecular outﬂow facility may, however, occur
in human subjects but there is conﬂicting data. Using
Schiotztonographylatanoprostexertedanapparenteﬀecton
pressure-sensitive outﬂow [34] whereas other studies using
alternative but seemingly valid techniques showed no eﬀect
on conventional outﬂow facility [35]. It is possible that the
increase in conventional outﬂow observed in human eyes
does not really exist [35]; this is the case in primate eyes. As
a model species for predicting the ocular eﬀects in humans,
the cynomolgus monkey should perhaps be regarded as very
useful but not infallible.
5. Conclusions
The data conﬁrm that bimatoprost exerts an eﬀect on
uveoscleral outﬂow by direct measurement in cynomol-
gus monkeys. Bimatoprost eﬀects on conventional outﬂow
observed in humans [26, 27] were not detected in monkeys.
In cynomolgus monkeys, bimatoprost appears to lower IOP
by exclusively increasing uveoscleral outﬂow.
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